OBJECTIVE: Renal transplantation is an outstanding therapy for end-stage renal failure and has been shown to increase life expectancy and quality of life, while reducing medical expenditure. The presence of IgM antibodies in recipient serum is not a contraindication for renal transplantation. However, the presence of this antibody may have significant clinical implications. IgM autoantibodies have been blamed for a group of accelerated or hyperacute cases of graft rejection. In this study, graft and patient survival outcomes after renal transplantation in LCM IgM-positive recipients have been assessed. MATERIALS AND METHODS: Data from 32 LCM IgM-positive kidney recipients who underwent renal transplantation at the Akdeniz University Transplantation Center between January 2006 and August 2008 were assessed. RESULTS: The mean age was 34 ± 13.5 (9-66). Twenty patients were male, and twelve were female. The mean length of therapy with dialysis was 22.94 ± 30.06 months (0-120). The duration of cold ischemia was 28.63 ± 5.85 minutes (21-42). CONCLUSION: Throughout the follow up period, the mean creatinine level was 1.3 mg/dL (0.69-4.5). Graft loss occurred in only one patient and was due to hemophagocytic syndrome and acute rejection. During follow up, creatinine elevation was seen in 12 patients (4%) in the early postoperative period. These patients were thought to have transplant rejection, and therapy for rejection was given. The therapy was successful. Graft survival was calculated to be 96 ± 3.5%, and none of the patients were lost.
OBJECTIVE: Renal transplantation is an outstanding therapy for end-stage renal failure and has been shown to increase life expectancy and quality of life, while reducing medical expenditure. The presence of IgM antibodies in recipient serum is not a contraindication for renal transplantation. However, the presence of this antibody may have significant clinical implications. IgM autoantibodies have been blamed for a group of accelerated or hyperacute cases of graft rejection. In this study, graft and patient survival outcomes after renal transplantation in LCM IgM-positive recipients have been assessed. MATERIALS AND METHODS: Data from 32 LCM IgM-positive kidney recipients who underwent renal transplantation at the Akdeniz University Transplantation Center between January 2006 and August 2008 were assessed. RESULTS: The mean age was 34 ± 13.5 (9-66). Twenty patients were male, and twelve were female. The mean length of therapy with dialysis was 22.94 ± 30.06 months (0-120). The duration of cold ischemia was 28.63 ± 5.85 minutes (21-42). CONCLUSION: Throughout the follow up period, the mean creatinine level was 1.3 mg/dL (0.69-4.5). Graft loss occurred in only one patient and was due to hemophagocytic syndrome and acute rejection. During follow up, creatinine elevation was seen in 12 patients (4%) in the early postoperative period. These patients were thought to have transplant rejection, and therapy for rejection was given. The therapy was successful. Graft survival was calculated to be 96 ± 3.5%, and none of the patients were lost.
Authors: C F Bryan; J Martinez; N Muruve; P W Nelson; G E Pierce; G Ross; C F Shield; B A Warady; M I Aeder; K M Harrell; T S Helling; A M Luger Journal: Clin Transplant Date: 2001 Impact factor: 2.863
Authors: A Sancho; E Gavela; J F Crespo; J L Górriz; A Avila; A Nuñez; P Molina; J L García-Ramos; J Montoro; L M Pallardó Journal: Nefrologia Date: 2006 Impact factor: 2.033
Authors: R H Kerman; B Susskind; I Buyse; P Pryzbylowski; J Ruth; S Warnell; S A Gruber; S Katz; C T Van Buren; B D Kahan Journal: Transplantation Date: 1999-12-27 Impact factor: 4.939
Authors: Aloke K Mandal; Jon J Snyder; David T Gilbertson; Allan J Collins; John R Silkensen Journal: Transplantation Date: 2003-02-27 Impact factor: 4.939